New therapy shows early promise in preventing FNAIT
Preclinical data from Rallybio suggested that RLYB212 may prevent fetal and neonatal allo-immune thrombocytopenia in high-risk pregnancies.
Megan Garlapow, PhD
Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC, where she brings extensive experience in medical communications across diverse therapeutic areas. Dr Garlapow earned her BA in biology from the University of Chicago and her PhD in genetics from North Carolina State University. With a strong background in biomedical science and genetics, Dr Garlapow has held key roles in medical education and clinical genetics and genomics, where she honed her skills in developing strategic proposals, securing funding, delivering high-quality educational content, and composing engaging medical journalism pieces.
